Clinical Trial

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (albumin bound) combined with octreotide long-acting injection in patients with unresectable or recurrent GEP-NETs.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-09.
Trial Details
NCT Number NCT07165886
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Gastroenteropancreatic Neuroendocrine Tumors
Enrollment 298 participants
Start Date 2025-08-29
Primary Completion 2028-08-29 (estimated)
Study Completion 2028-08-29 (estimated)
Updated on ClinicalTrials.gov 2026-04-24